IVR-101

IVR-101 is a topical gel formulation developed by Ivrea Pharmaceuticals for the treatment of onychomycosis (fungal nail infections). It utilizes a proprietary delivery system designed to transport fungicidal allylamines, such as terbinafine, through the nail plate to the underlying infection site. By achieving high local concentrations of the active ingredient, IVR-101 aims to match the efficacy of oral antifungal therapies while maintaining the safety profile of topical applications. The product has successfully completed Phase II clinical trials and demonstrated effective nail penetration in human cadaver nail studies.